

JAN 12 2007

Appl. No. 10/688,100
Supplemental Amendment
Page 3 of 7

Attorney Docket No.: 08321-0082-D12

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1 (currently amended) A method of inhibiting Vif multimerization in a subject comprising administering an effective amount of a Vif antagonist to the subject, wherein the Vif antagonist binds to the multimerization domain within a Vif protein, and the Vif antagonist is a peptide comprising a PXP motif, wherein X is any one amino acid.
2. (currently amended). The method of claim 1, wherein the Vif antagonist is ~~an anti-Vif antibody~~, or a Vif protein fragment which comprises at least SEQ ID NO: 25.
3. (canceled).
4. (previously presented) The method of claim 2, wherein the Vif protein fragment is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 26.
5. (canceled).
- 6 (canceled).
7. (canceled).
8. (canceled)
9. (currently amended). The method of claim 1 8, wherein the any one amino acid is selected from the group consisting of Arg, Val, Pro, Ser, Leu, Phe, Ala, His and Tyr.
10. (canceled).

Appl. No. 10/688,100
Supplemental Amendment
Page 4 of 7

Attorney Docket No.: 08321-0082-DI2

11. (canceled)
12. (previously presented) The method of claim 1, wherein the peptide comprising the PXP motif is 4 to 20 amino acids long.
13. (previously presented) The method of claim 12, wherein peptide comprising the PXP motif is 5 to 20 amino acids long.
14. (previously presented) The method of claim 12, wherein peptide comprising the PXP motif is 12 amino acids long.
15. (previously presented) The method of claim 1, wherein the peptide comprising the PXP motif is selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20.
16. (canceled)
17. (original). The method of claim 1, wherein the Vif antagonist is a molecule comprising one or more peptides comprising a PXP motif.
18. (canceled)
19. (original) The method of claim 1, wherein the Vif antagonist is administered parenterally or enterally.
20. (original) The method of claim 1, wherein the Vif antagonist is administered locally.
21. (previously presented) The method of claim 1, wherein the peptide comprising the PXP motif comprises the sequence SEQ ID NO: 11.

Appl. No. 10/688,100
Supplemental Amendment
Page 5 of 7

Attorney Docket No.: 08321-0082-DI2

22. (previously presented) The method of claim 21 wherein the peptide comprising the PXP motif consists of the sequence SEQ ID NO: 11.